^
Association details:
| Biomarker: | PLK4 expression |
|---|---|
| Cancer: | Leiomyosarcoma |
| Drug: | ocifisertib (CFI-400945) (PLK4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Improvement of drug efficacy of polo-like kinase 4 inhibitor in the treatment of uterine leiomyosarcoma.
Published date:
05/15/2020
Excerpt:
Ut-LMS cell lines expressed high levels of PLK4 and were highly sensitive (IC50 in nM range) to CFI-400945.
